AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29146139 — intervention group
Group type: COMPARATOR
Intervention: Supplemental nutrition drinks (250 kcal/day) for HIV-negative hemodialysis patients (Group 2)
Number of subjects: 23
Study 29146139 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements for Group 1
Number of subjects: 23
Study 29146139 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements for Group 2
Number of subjects: 23
Study 26727338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 187
Study 26727338 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 187
Study 23887347 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 80
Study 23887347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin
Number of subjects: 80
Study 23887347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiamine and cobalamin
Number of subjects: 80
Study 23887347 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 80
Study 23887347 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine, Cobalamin, Combination groups
Number of subjects: 80
Study 22918557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (2,340 kJ, 70 % CHO, 12 % protein)
Number of subjects: 11
Study 22918557 — intervention group
Group type: COMPARATOR
Intervention: High-protein meal (35 % CHO, 48 % protein)
Number of subjects: 11
Study 21162508 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior soft tissue repair
Number of subjects: 276
Study 21162508 — intervention group
Group type: COMPARATOR
Intervention: No posterior soft tissue repair
Number of subjects: 276
Study 19123324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallux-trampling (HT) plus Yaotongling suppository (YS)
Number of subjects: 108
Study 19123324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallux-trampling (HT) plus placebo suppository
Number of subjects: 108
Study 19123324 — intervention group
Group type: COMPARATOR
Intervention: Yaotongling suppository (YS) plus mock HT
Number of subjects: 108
Study 17704027 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple sweet potato leaves (PSPLs) diet (daily consumption of 200 g PSPLs)
Number of subjects: 15
Study 17704027 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low polyphenol, with carotenoids adjusted to PSPLs level)
Number of subjects: 15
Study 12602532 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (477 mg twice daily)
Number of subjects: 18
Study 12602532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12602532 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (954 mg during short study)
Number of subjects: 18
Study 12602532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in short study)
Number of subjects: 18
Study 10827374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 67000
Study 10827374 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-factor subgroup analyses
Number of subjects: 67000
Study 10827374 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial prognostic subgroups
Number of subjects: 67000
Study 9236628 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose Gd-DTPA (0.3 mmol/kg)
Number of subjects: 50
Study 9236628 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Gd-DTPA with MT and short delay
Number of subjects: 50
Study 9236628 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose Gd-DTPA with MT and short delay
Number of subjects: 50
Study 9236628 — intervention group
Group type: EXPERIMENTAL
Intervention: MT imaging with long delay following triple-dose Gd-DTPA
Number of subjects: 50
Study 8398056 — intervention group
Group type: EXPERIMENTAL
Intervention: Talcid suspension (hydrotalcit)
Number of subjects: 18
Study 8398056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3096543 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey A.D.E. system (Mapleson 'E' mode, lever down)
Number of subjects: 10
Study 3096543 — intervention group
Group type: COMPARATOR
Intervention: Bain system (Mapleson D/E)
Number of subjects: 10
Study 29874972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy
Number of subjects: 15
Study 29874972 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser therapy)
Number of subjects: 15
Study 26757270 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg qd + promestriene vaginal capsules intravaginally (Group A)
Number of subjects: 104
Study 26757270 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg qd (Group B)
Number of subjects: 104
Study 26757270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 24962003 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mmol l(‐1) Na(+)
Number of subjects: 8
Study 24962003 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mmol l(‐1) Na(+)
Number of subjects: 8
Study 24962003 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 8
Study 24962003 — intervention group
Group type: COMPARATOR
Intervention: 60 mmol l(‐1) Na(+)
Number of subjects: 8
Study 22966894 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making training for general practitioners
Number of subjects: 1200
Study 22966894 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment)
Number of subjects: 1200
Study 19679506 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Hip Extension with abdominal hollowing and active GM contraction for 10 minutes
Number of subjects: 20
Study 19679506 — intervention group
Group type: COMPARATOR
Intervention: Prone Hip Extension only (control group)
Number of subjects: 20
Study 18774563 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: IUD guidance during hysteroscopic adhesiolysis with early intervention
Number of subjects: 71
Study 18774563 — intervention group
Group type: COMPARATOR
Intervention: Group 2: IUD guidance during hysteroscopic adhesiolysis without early intervention
Number of subjects: 71
Study 16195478 — intervention group
Group type: EXPERIMENTAL
Intervention: LPLS447X carriers
Number of subjects: 10
Study 12952998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics consultation offered (n = 278)
Number of subjects: 551
Study 12952998 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 273)
Number of subjects: 551
Study 10801917 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally heated tomatoes (not homogenized)
Number of subjects: 33
Study 10801917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly heated tomatoes (mildly homogenized)
Number of subjects: 33
Study 10801917 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively heated tomatoes (severely homogenized)
Number of subjects: 33
Study 10801917 — intervention group
Group type: COMPARATOR
Intervention: Additional heating (compared to minimal heating)
Number of subjects: 33
Study 8699333 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulated tablet formulation of nadolol (80 mg) - single dose
Number of subjects: 20
Study 8699333 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed tablet formulation of nadolol (80 mg) - single dose
Number of subjects: 20
Study 8699333 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulated tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Number of subjects: 20
Study 8699333 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Number of subjects: 20
Study 1379056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 17.5 mg and 3% Dextran 70 7.5 ml kg‐1 before delivery (group A)
Number of subjects: 2
Study 1379056 — intervention group
Group type: COMPARATOR
Intervention: Volume loading with Dextran 15 ml kg‐1 without infusion of ephedrine (group B)
Number of subjects: 2
Study 6384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by flap procedures
Number of subjects: 17
Study 6384466 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 17
Study 6384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing alone and scaling and root planing followed by flap procedures
Number of subjects: 17
Study 30935296 — intervention group
Group type: EXPERIMENTAL
Intervention: Deload-tape
Number of subjects: 27
Study 30935296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham-tape
Number of subjects: 27
Study 30935296 — intervention group
Group type: COMPARATOR
Intervention: No-tape
Number of subjects: 27
Study 29938898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)
Number of subjects: 20
Study 29938898 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg)
Number of subjects: 20
Study 29938898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27054860 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste and 0.075% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 36
Study 27054860 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste
Number of subjects: 36
Study 27054860 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste and CPC mouthrinse
Number of subjects: 36
Study 23810648 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenneth Jones ACL reconstruction
Number of subjects: 120
Study 23810648 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenneth Jones ACL reconstruction + extra-articular ilio-tibial band tenodesis
Number of subjects: 120
Study 23810648 — intervention group
Group type: COMPARATOR
Intervention: Kenneth Jones ACL reconstruction alone
Number of subjects: 120
Study 21910547 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of TOVA
Number of subjects: 0
Study 21910547 — intervention group
Group type: COMPARATOR
Intervention: Afternoon administration of TOVA
Number of subjects: 0
Study 21910547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of inattention
Number of subjects: 0
Study 21910547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of hyperactivity and impulsivity
Number of subjects: 0
Study 20974316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30, 60, and 90 mg once daily
Number of subjects: 0
Study 20974316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 or 60 mg once daily
Number of subjects: 0
Study 20974316 — intervention group
Group type: COMPARATOR
Intervention: Dexlansoprazole 60 and 90 mg once daily
Number of subjects: 0
Study 20974316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18726104 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous gentamicin, administered 30 min before surgery.
Number of subjects: 88
Study 18726104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics).
Number of subjects: 88
Study 15652875 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive TMS (rTMS) at 5 Hz, 20 sessions (5 sessions per week) of 120% of motor threshold and 1250 pulses per session, concomitantly taking amitriptyline (mean dose 110 mg/d)
Number of subjects: 46
Study 15652875 — intervention group
Group type: COMPARATOR
Intervention: Sham repetitive TMS (sham)
Number of subjects: 46
Study 11942669 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE level A
Number of subjects: 16
Study 11942669 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE level B
Number of subjects: 16
Study 11942669 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload task
Number of subjects: 16
Study 11942669 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE levels A and B
Number of subjects: 16
Study 11942669 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate during workload task
Number of subjects: 16
Study 11942669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway measurements
Number of subjects: 16
Study 9470324 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin sodium (Dilantin)
Number of subjects: 16
Study 9470324 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A
Number of subjects: 16
Study 9470324 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand C
Number of subjects: 16
Study 9470324 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand B
Number of subjects: 16
Study 7637405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 686
Study 7637405 — intervention group
Group type: COMPARATOR
Intervention: Other providers (medical doctors)
Number of subjects: 686
Study 2719366 — intervention group
Group type: EXPERIMENTAL
Intervention: Actidose‐Aqua 25 g
Number of subjects: 12
Study 2719366 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Char 25 g
Number of subjects: 12
Study 2719366 — intervention group
Group type: COMPARATOR
Intervention: Control (no charcoal)
Number of subjects: 12
Study 53428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (H.B.I.G.)
Number of subjects: 561
Study 53428 — intervention group
Group type: COMPARATOR
Intervention: Immune serum globulin (I.S.G.)
Number of subjects: 561
Study 31565952 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel only
Number of subjects: 153
Study 31565952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure garment therapy only
Number of subjects: 153
Study 31565952 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical silicone gel and pressure garment therapy
Number of subjects: 153
Study 31021419 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perception of excessive infant crying at 6 months
Number of subjects: 0
Study 31021419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerable adult attachment style, previous maternal mental health difficulties, low paternal education, paternal involvement with the child, and not being married
Number of subjects: 0
Study 24806033 — intervention group
Group type: EXPERIMENTAL
Intervention: TVR 2250 mg
Number of subjects: 81
Study 24806033 — intervention group
Group type: EXPERIMENTAL
Intervention: TVR 1500 mg
Number of subjects: 81
Study 23257888 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% levobupivacaine injected at T10, T11, and T12 paravertebral spaces
Number of subjects: 60
Study 23257888 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 0.9% NaCl solution
Number of subjects: 60
Study 21329495 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly report card mailings
Number of subjects: 5457
Study 21329495 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care distribution of report cards
Number of subjects: 5457
Study 21329495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level provider performance feedback
Number of subjects: 5457
Study 21329495 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 5457
Study 19253124 — intervention group
Group type: EXPERIMENTAL
Intervention: LNIT with Der p-coated strips
Number of subjects: 35
Study 19253124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 16572610 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg (oral preoperative dose)
Number of subjects: 77
Study 16572610 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 100 mg (2 IM doses before surgery and after 12 hours)
Number of subjects: 77
Study 10394514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry
Number of subjects: 74
Study 8742199 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 8742199 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 1679449 — intervention group
Group type: EXPERIMENTAL
Intervention: n-propanol (50% v/v) and isopropanol (30% v/v) with cosmetic additives
Number of subjects: 20
Study 1679449 — intervention group
Group type: COMPARATOR
Intervention: isopropanol 60% v/v (standard control)
Number of subjects: 20
Study 1679449 — intervention group
Group type: EXPERIMENTAL
Intervention: n-propanol (50% v/v) and isopropanol (30% v/v) without cosmetic additives
Number of subjects: 20
Study 6310241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (mean dose 0.5 micrograms daily)
Number of subjects: 17
Study 6310241 — intervention group
Group type: COMPARATOR
Intervention: D3 (dose 100 micrograms daily)
Number of subjects: 17
Study 31731109 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine (300-1200 mg/day)
Number of subjects: 685
Study 31399047 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual face-to-face brief motivational interviewing (MI) with generic advice on selected health behaviour, plus brief MI messages via WhatsApp/WeChat for 6 months
Number of subjects: 60
Study 31399047 — intervention group
Group type: COMPARATOR
Intervention: Control group with no MI and booster interventions
Number of subjects: 60
Study 29893182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) delivered in group sessions once a week for eight weeks
Number of subjects: 48
Study 29893182 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with citalopram (30-50 mg/day at therapeutic dosages)
Number of subjects: 48
Study 26231684 — intervention group
Group type: EXPERIMENTAL
Intervention: CICADA method (CeasIng Cpap At standarD criteriA)
Number of subjects: 50
Study 24939812 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessment and immediate rehabilitation
Number of subjects: 0
Study 24939812 — intervention group
Group type: COMPARATOR
Intervention: Functional assessment and rehabilitation as usual
Number of subjects: 0
Study 24939812 — intervention group
Group type: COMPARATOR
Intervention: Assessment as usual and immediate rehabilitation
Number of subjects: 0
Study 24939812 — intervention group
Group type: COMPARATOR
Intervention: Assessment and rehabilitation as usual
Number of subjects: 0
Study 22463125 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intensive intervention of nutrition and exercise education, coping skills training and exercise (Phase I), followed by 9 months of continued monthly contact (Phase II) and then 6 months follow-up on their own.
Number of subjects: 358
Study 22463125 — intervention group
Group type: COMPARATOR
Intervention: Experimental group (receiving the intervention)
Number of subjects: 358
Study 20135645 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 140
Study 20135645 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 140
Study 20135645 — intervention group
Group type: COMPARATOR
Intervention: Other NSAIDs
Number of subjects: 140
Study 20135645 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, Statins, Other NSAIDs
Number of subjects: 140
Study 18084988 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fascia iliaca compartment block with 30 ml 0.5% bupivacaine with 1:200,000 adrenaline, 150 microg clonidine and 9 ml 0.9% saline
Number of subjects: 44
Study 18084988 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 40 ml 0.9% saline
Number of subjects: 44
Study 16046714 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS/fiber formula (5.1 g/L FOS and 8.9 g/L fiber)
Number of subjects: 10
Study 16046714 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS/fiber formula
Number of subjects: 10
Study 12404081 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (65 mg) consumed in de-caffeinated coffee at 1000, 1100, 1200, and 1300 hours
Number of subjects: 24
Study 12404081 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg) consumed at 1300 hours
Number of subjects: 24
Study 12404081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (de-caffeinated coffee)
Number of subjects: 24
Study 11783152 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin with conventional treatment
Number of subjects: 0
Study 11783152 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 0
Study 7848120 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of subcutaneous sumatriptan
Number of subjects: 20
Study 7848120 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group during attack)
Number of subjects: 20
Study 7848120 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group after treatment)
Number of subjects: 20
Study 1983346 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose H2-blockade with ranitidine 300 mg q.d.s.
Number of subjects: 36
Study 1983346 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose H2-blockade with ranitidine 1200 mg o.m.
Number of subjects: 36
Study 1983346 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose H2-blockade with sufotidine 600 mg b.d.
Number of subjects: 36
Study 1983346 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 30994312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 64
Study 30994312 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (Control)
Number of subjects: 64
Study 30031272 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit training method
Number of subjects: 20
Study 30031272 — intervention group
Group type: COMPARATOR
Intervention: Explicit training method
Number of subjects: 20
Study 26689707 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (everolimus- or zotarolimus-eluting stent)
Number of subjects: 1257
Study 26689707 — intervention group
Group type: COMPARATOR
Intervention: Early-generation drug-eluting stents (paclitaxel- or sirolimus-eluting stent)
Number of subjects: 1257
Study 25311699 — intervention group
Group type: EXPERIMENTAL
Intervention: Metofluthrin mosquito coils (spatial repellent)
Number of subjects: 180
Study 25311699 — intervention group
Group type: COMPARATOR
Intervention: Placebo mosquito coils
Number of subjects: 180
Study 23049928 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text message support intervention
Number of subjects: 271
Study 20948256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with S‐1 (more than 50% of the total scheduled dose)
Number of subjects: 47
Study 20948256 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with S‐1 (less than 50% of the total scheduled dose)
Number of subjects: 47